N. Jacobs

Cumulative Morbidity and Late Mortality in Long-Term Survivors of Exocrine Pancreas Cancer

M. Farnell, F. Que, RobertI Miller, 2009, Journal of gastrointestinal cancer.

Regorafenib dose optimization study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC)–An ACCRU Network study.

J. Sloan, M. Lacouture, A. Barzi, 2018 .

52-year-old woman with intractable nausea and vomiting.

Jonathan H. Smith, R. Ficalora, N. Jacobs, 2010, Mayo Clinic proceedings.

Pre-Emptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial.

J. Sloan, B. Pasche, M. Lacouture, 2021, The oncologist.

Endoscopic diagnosis and treatment of esophageal verrucous squamous cell cancer.

L. M. Wong Kee Song, S. Sweetser, N. Jacobs, 2014, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.

Afsaneh Barzi, Katrina Pedersen, Jeannine S McCune, 2019, The Lancet. Oncology.

Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count

D. Steensma, A. Tefferi, S. Markovic, 2010, American journal of hematology.

Prospective validation of genetic predictors of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) in a racially diverse cohort: Results from ECOG-ACRIN E1Z11.

A. Benson, J. Sparano, C. Loprinzi, 2021 .